Date	Event
March 26, 2001	Notification of funding to Endovasc after approval of project by the PM External Research Program-Science Advisory Board.
July 1, 2001:	Effective date (start date) as on the Agreement. The 1st year Research Agreement for the two-year research proposal "Development and evaluation of therapeutic delivery systems for administration of nicotine (NRA) in vascular diseases", PI: Dr. Diane Dottavio, Ph.D. of Endovasc Ltd. Inc.; $ 511,829.
November 21, 2001:	Five-month progress report received.
April 30, 2002:	Ten-month progress report received (two animal studies were reported to be completed).
June 2002:	Dr. Dottavio requested change in key personnel (from Dr. Cooke to Drs. Virmani and Kolodgie) and the request was forwarded to the PMERP-SAB.
July 3, 2002:	Dr. Dottavio requested a change in scope with a change in budget to include biodegradable nicotine delivery device. The request was forwarded to the PMERP-SAB.
July 29, 2002:	Dr. Dottavio retracts request for change in key personnel.
August 5, 2002:	PMERP-SAB did not approve the change of scope request with budget change.
September 27, 2002:	Amendment to the External Research Agreement to cover 2nd year project; $217,870.

Payment status: We have paid in full for the first year and the check for the 1st quarter of the 2nd (and final) year is ready for mailing.

DRAFT: For discussion purpose only. TKS 11/6/02

Source: https://www.industrydocuments.ucsf.edu/docs/ylfk0001

Comments:

- Funding decision to support this project was made in 2001, and not (as stated in the Endovasc press release) in the year 2000.

- Nicotine (also synonymously called NRA or nicotine receptor agonist in the title, proposal, and progress reports) is the compound studied in the ERP Project. Angiogenix ™ was never mentioned in the proposal or progress reports. The exact formulation of Angiogenix ™ or its similarity (if any) with nicotine was never discussed with us.

- Research objectives (as in the original proposal): "Aims: It is the specific aim of this grant proposal to develop site-directed delivery systems, which administer extremely low, therapeutic levels of nicotine receptor agonist (NRA) to ischemic areas over extended periods of time. We wish to compare the effects achieved by administration of (a) nicotine-loaded liposomes and (b) NRA-coated stent implants to results achieved by oral administration of NRA in appropriate animal models. We hope to show that our delivery systems: 1) enhance the therapeutic effects of nicotine; 2) lower the dosage necessary to achieve efficacy; 3) eliminate the toxic effects seen at high doses; and 4) greatly reduce the risk of tumor or plaque angiogenesis incurred by smoked nicotine administration. We believe our delivery systems will greatly enhance the safety of nicotine treatment in vascular diseases such as therapeutic angiogenesis."

- Animal tests at Columbia University: External Research Program-funded pig study to investigate the angiogenic potency of injected nicotine (Angiogenix™ not mentioned).

- It was mentioned in the 10-month progress report that the results of the pig study (with nicotine) would be submitted in abstract form to be presented at the American College of Angiology meeting in Hawaii, October 13-18, 2002. We have not received the abstract from Dr. Dottavio yet.

PM3001180904

Source: https://www.industrydocuments.ucsf.edu/docs/ylfk0001